Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.42 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989942 | 0.91 | RIPK1 (0.45) | RIPK1PTGER1L3MBTL1HTTGPR6 | |
| SCHEMBL30989921 | 0.89 | RIPK1 (0.45) | RIPK1HAO1PTGER1NLRP3SCN9A | |
| SCHEMBL30989822 | 0.85 | RIPK1 (0.42) | RIPK1NLRP3SCN9APTGER4HTT | |
| SCHEMBL30989923 | 0.84 | ALDH1A1 (0.47) | RIPK1PTGER4PTGER2HTT | |
| SCHEMBL30989808 | 0.83 | HTT (0.39) | SCN9APTGER4PTGER2HTT | |
| SCHEMBL30989793 | 0.81 | HTT (0.38) | SCN9APTGER4PTGER2HTT | |
| SCHEMBL30989912 | 0.80 | HTT (0.37) | SCN9APTGER4PTGER2HTT | |
| SCHEMBL30989806 | 0.79 | GRM5 (0.45) | RIPK1HTT | |
| SCHEMBL30989936 | 0.78 | RIPK1 (0.47) | RIPK1L3MBTL1GPR6 | |
| SCHEMBL30989812 | 0.78 | MEP1B (0.44) | RIPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |